Activity/Study
Status
Results expected
Production of recombinant molecule and variant(s)
Quantities to cover validation phase
Completed
Bioequivalence study in animal model and dose response
Completed
Preliminary pharmacokinetic study
Completed
Lead Validation
Completed
Mechanism of action studies
Completed
Ongoing
1Q 2022
Ongoing
1Q 2022
Ongoing
1Q 2022
Production of novel variants
Ongoing
3Q 2021
Cellular Assays on novel variants
Ongoing
3Q 2021
Pharmacokinetic studies
Ongoing
4Q 2021
Animal model studies
Early 2022
1Q 2022
Completion of Lead Optimization phase
1Q 2022
Activity/Study
Production of recombinant molecule and variant(s)
Status: Completed
Quantities cover validation and preclinical studies
Status: January 2019
Bioequivalence study in animal models and dose response
Status: April 2019
Results expected: June 2019
Pharmacokinetics study
Status: selection of CRO
Results expected: Q2 2019
Postdoc study on mechanism of action, UZH
Status: April 2019
Results expected: Q3 2019
GBCHpVac has secured exclusive, worldwide commercialization rights to GBC-R1 from the University of Zurich.
In a first phase, GBC SA has financed the patenting of GBC-R1. See also WO2015/114575 and WO2015/144576.